Venetoclax is approved for the treatment of relapsed/refractory del17p chronic lymphocytic leukemia (CLL) and has shown activity in patients following the failure of kinase inhibitors. However, there is a lack of data availlable for outcomes, toxicities and the dose ramp-up period in the real world, as well as treatment selection following discontinuation. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the results of a retrospective study analyzing the largest cohort of venetoclax-treated patients to date, from across almost 20 US and international academic and community centers. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Retrospective multicenter analysis of venetoclax-treated CLL patients
